

FOR IMMEDIATE RELEASE



IntegraGen Announces Launch of GeCo - Advanced Genomic Consulting Service

IntegraGen Genomics will now offers advanced statistical support to help researchers analyze and interpret complex genomic data

Evry, France (February 6, 2015) – IntegraGen Genomics (FR0010908723 - ALINT), a leading provider of project-based genomic services, announced today the launch of GeCo, an advanced genomic consulting service offering directed towards academic and corporate genomics researchers. GeCo provides researchers with access to leading experts in the field of biostatistics and bioanalytics and offers researcher support for the advanced and personalized statistical analysis of genomic data ranging from the initial design of genomic research projects to the detailed evaluation of research results. IntegraGen Genomics will begin offering this service immediately.

"GeCo will allow us to provide an advanced level of service to our customers who are implementing genomic research projects," stated Emmanuel Martin, Director of Sales and Marketing for IntegraGen Genomics. "The complexity of data resulting from next-generation sequencing projects and other genomic research projects using other newer technologies has led many of our customers to ask for our support with the analysis of their data. GeCo will allow us to meet this need and build upon our current service offerings by combining our rapid and high-quality analysis of genomic material with access to advanced statistical analytics tools and experts."

Examples of services GeCo offers include scientific advice and design of Statistical Analysis Plans (SAP) for genomic research projects, the analysis of exome sequencing and RNA-Seq results, analysis of data from genome-wide association studies (GWAS), and the use of data analysis to develop figures and tables to assist with the visualization of research results to be included in publications. A more complete list of the types of genomic research projects GeCo can provide expert analytical support for can be found at on [IntegraGen's website](#).

ABOUT INTEGRAGEN

IntegraGen is a company specialized in deciphering the human genome by performing genomic analyses for academic and private laboratories and developing diagnostic tools within the fields of oncology and autism. IntegraGen's oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. For autism, IntegraGen has developed the ARISK® Test, the first test marketed in the United States to assess the risk of autism spectrum disorder in children.

As of December 31 2014, IntegraGen had 34 employees and had generated revenue of €6 million in 2014. Based in the Evry Genopole, IntegraGen also has an office in the Cambridge, Massachusetts in the United States. IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information on IntegraGen visit www.integragen.com.

CONTACT

INTEGRAGEN

Emmanuel MARTIN
Sales and Marketing Director
IntegraGen Genomics
services@integragen.com
Tel.: +33 (0)1 60 91 09 00

